CoChat

Antihyperglycemic drugs use and new-onset atrial fibrillation: A population-based nested case control study

Open access

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Currently, the potential risk of atrial fibrillation associated with antihyperglycemic drug use has been a topic of considerable interest. However, it remains uncertain whether different classes of antihyperglycemic drug therapy are associated with the risk of atrial fibrillation risk. Here, we investigated the association between different classes of antihyperglycemic drugs and new-onset atrial fibrillation (NAF). A case-matched study was performed based on the National Health Insurance Program in Taiwan. Patients who had NAF were considered the NAF group and were matched in a 1:4 ratio with patients without NAF, who were assigned to the non-NAF group. Patients were matched according to sex, age, diabetes mellitus duration, index date, and Charlson Comorbidity Index score. We used multivariate logistic regression controlling for potential confounders to examine the association between different classes of antihyperglycemic drug use and the risk of NAF. Overall, we identified 2,882 cases and 11,528 matched controls for the study. After adjusting for sex, age, comorbidities, and concurrent medications, users of biguanides or thiazolidinediones were at a lower risk of developing NAF when compared with non-users (odds ratio [OR] 0.81, 95% confidence interval [CI] 0.71-0.95 and OR 0.72, 95% CI 0.63-0.83, respectively). In contrast, users of insulin were at a higher risk of developing NAF than were non-users (OR 1.19, 95% CI 1.06-1.35). Sulfonylureas, glinides, α-glucosidase inhibitors, and dipeptidyl peptidase-4 inhibitors were not associated with developing the risk of NAF. In conclusion, the use of biguanides or thiazolidinediones may be associated with a low risk of NAF, whereas insulin may be associated with a significant increase in the risk of NAF in patients with type 2 diabetes mellitus during long-term follow-up. Further prospective randomized studies should investigate which specific class of antihyperglycemic drug treatment for diabetes mellitus can prevent or postpone NAF.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0197245

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Flowchart of selection of patients for the inclusion in this study.
Fig 1 Flowchart of selection of patients for the inclusion in this study.CC BY · PubMed Central
Fig 2 Risk of antihyperglycemic drugs on the ORs for new-onset atrial fibrillation between two groups of patients. A: Crude estimates of all antihyperglycemic drugs. *p value < 0.05.
Fig 2 Risk of antihyperglycemic drugs on the ORs for new-onset atrial fibrillation between two groups of patients. A: Crude estimates of all antihyperglycemic drugs. *p value < 0.05.CC BY · PubMed Central
Fig 3 Adjusted for age, sex, comorbidities, and concurrent medication estimates of all antihyperglycemic drugs. *p value < 0.05.
Fig 3 Adjusted for age, sex, comorbidities, and concurrent medication estimates of all antihyperglycemic drugs. *p value < 0.05.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

Metadata

Authors
Liou, Y.-S., Yang, F.-Y., Chen, H.-Y., & Jong, G.-P.
Affiliations
  • Taichung Veterans General Hospital (TW)
  • China Medical University (TW)
  • Chung Shan Medical University Hospital (TW)
Corresponding author
Jong, Gwo-Ping
Venue
PLOS ONE
Published
2018-08-30
Volume
13
Issue
8
Pages
e0197245
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2889208017
Cited by
75
References
38
Citations by year
2026: 9 · 2025: 9 · 2024: 7 · 2023: 7 · 2022: 20 · 2021: 8 · 2020: 7 · 2019: 7 · 2018: 1
FWCI
4.34
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Chung Shan Medical University Hospital (2016-012)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Keywords
new-onset atrial fibrillation, antidiabetic drugs, type 2 diabetes, biguanides, thiazolidinediones, insulin, sulfonylureas, glinides, alpha-glucosidase inhibitors, DPP-4 inhibitors
MeSH terms
Aged, Atrial Fibrillation, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Risk Factors, Sulfonylurea Compounds, Taiwan, Case-Control Studies, Age of Onset, Dipeptidyl-Peptidase IV Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.